All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
During the EHA 2022 Congress, the ALL Hub was pleased to speak to Anita Rijneveld, Erasmus MC, Rotterdam, NL. We asked, Does adding blinatumomab to frontline therapy improve survival outcomes for adults with B-ALL?
Does adding blinatumomab to frontline therapy improve survival outcomes for adults with B-ALL?
Rijneveld begins by stating the importance of MRD negativity in improving outcomes of ALL. Rijneveld then discusses the results of her phase II study, in which patients were given blinatumomab after consolidation therapy. Finally, Rijneveld talks about the D-ALBA trial, and using blinatumomab in combination with other drugs.
A review of antibody and cellular immunotherapies for adults with relapsed/refractory ALL
The median age of diagnosis of acute lymphoblastic leukemia (ALL) in the United States is 16 years old, making it mainly a disease of children and adolescents;...
How should we best sequence the new targeted therapies in relapsed B-ALL?
During the 8th Annual Meeting of the Society of Hematologic Oncology (SOHO), the ALL Hub spoke to Emily Curran, University of Cincinnati, Cincinnati, US. We asked, How should...
Subscribe to get the best content related to ALL delivered to your inbox